The U.S. Food and Drug Administration (FDA) has granted SELZENTRY™ (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals. SELZENTRY was originally granted accelerated conditional approval in August 2007 based on 24-week data from pivotal Phase 3 studies. SELZENTRY now becomes the latest fully approved treatment for HIV.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments